Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 19, 2026
Reporting Period: Single event date (August 19, 2026)
This filing reports the unregistered sale of equity securities in the form of a stock option grant to a new employee.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This is a current report focused on a specific corporate action rather than a periodic financial statement.
Material Changes and Event Details
Item 3.02: Unregistered Sales of Equity Securities
- Event: Grant of stock options to a new employee as a material inducement for employment.
- Shares Granted: 307,814 shares of common stock.
- Exercise Price: $5.76 per share (closing price on August 19, 2026).
- Term: Ten years.
- Vesting Schedule: Four-year vesting period; 25% vests on the first anniversary, with the remainder vesting in equal monthly installments thereafter, contingent on continued service.
- Approval: Approved by the Compensation Committee.
- Regulatory Basis: Issued outside of equity incentive plans under the Nasdaq Listing Rule 5635(c)(4) employment inducement exception and exempt from registration under Section 4(a)(2) of the Securities Act and Regulation D.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future performance, or specific risk factors beyond the standard restriction that the options and underlying shares cannot be sold in the United States absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the impact of the 307,814 new options on potential future dilution.
- Confirm the identity and role of the new employee receiving the inducement award.
- Review the referenced Exhibit 10.9 from the August 14, 2026 Form 10-Q for the full terms of the option agreement.
- Monitor future filings for any changes in the company's capital structure resulting from option exercises.